临床ICS治疗方案下，部分哮喘患者症状仍不能得到较好控制，提示哮喘的发生可能有新机制。最新研究表明，病理状态下肠道静息态ILC2s（nILC2s）可转化为炎性ILC2s（iILC2s），经特异性趋化因子S1P作用募集至肺，继而诱发气道炎症。课题组发现，傣药铜钱麻黄总黄酮和其中1个黄酮能明显改善哮喘小鼠肺组织病理变化，显著降低肺泡灌洗液中ILC2s上下游炎性细胞因子水平，减少小肠和肺ILC2s及肺iILC2s数目，推测铜钱麻黄可能是通过调节iILC2s在“肠-肺轴”的迁移而干预哮喘。本研究以活性为导向，从铜钱麻黄总黄酮中分离和寻找活性化合物，采用流式细胞术、多光谱组织成像技术、RT-qPCR和目标蛋白过表达等技术结合铜钱麻黄的傣医药理论，研究总黄酮和活性单体对小肠组织iILC2s的生成、转化和趋化的影响，同时探寻其可能的作用分子或途径，为哮喘治疗提供新策略，也为该药的进一步开发提供科学依据。

The symptoms of some asthma patients still can not be completedly relieved by using ICS for asthma treatment, suggesting an unveiled mechanism for the occurrence of asthma. The latest study indicated that small intestinal natural ILC2s (nILC2s) can be transformed into inflammatory ILC2s (iILC2s) under certain pathological conditions, and recruited to the lungs by specific chemokine S1P, which in turn induces airway inflammation. We found that the total flavonoids and one compound isolated from Shuteria sinensis significantly improved the pathological changes of lung tissue in asthmatic mice, reduced the levels of inflammatory cytokines in the upper and lower reaches of ILC2s in BALF, and decreased the amount of ILC2s in intestine and lung and the amount of iILC2s in lung. Thus we supposed that S. sinensis may relieve asthma symptoms by regulating the migration of iILC2s in the "intestinal-lung axis". In this study, compounds will be separated from the total flavonoids of S. sinensis under activity-guiding. Combined with the theory of Dai medicine, activity studies with the flow cytometry, multiplexed immunofluorescence images, RT-qPCR and target protein overexpression are used to elusidate the effects of flavonoids on the formation, transformation and chemotaxis of iILC2s in small intestine, and the possible mechanism action. This work will provide a new strategy for the treatment of asthma and scientific data for the development of the medicine.